333 related articles for article (PubMed ID: 37370736)
21. Dermatologic adverse events associated with targeted therapies for melanoma.
Scarpato L; Festino L; Vanella V; Madonna G; Mastroianni M; Palla M; Ascierto PA
Expert Opin Drug Saf; 2022 Mar; 21(3):385-395. PubMed ID: 34595993
[TBL] [Abstract][Full Text] [Related]
22. Safety Profiles and Pharmacovigilance Considerations for Recently Patented Anticancer Drugs: Cutaneous Melanoma.
Basile D; Lisanti C; Pizzichetta MA; Baldo P; Fornasier G; Lo Re F; Corona G; Puglisi F
Recent Pat Anticancer Drug Discov; 2019; 14(3):203-225. PubMed ID: 31362664
[TBL] [Abstract][Full Text] [Related]
23. Dermoscopy in the era of dermato-oncology: from bed to bench side and retour.
Woltsche N; Schwab C; Deinlein T; Hofmann-Wellenhof R; Zalaudek I
Expert Rev Anticancer Ther; 2016 May; 16(5):531-41. PubMed ID: 26999650
[TBL] [Abstract][Full Text] [Related]
24. [What's new in dermato-oncology?].
Basset-Séguin N
Ann Dermatol Venereol; 2011 Dec; 138 Suppl 4():S253-62. PubMed ID: 22202647
[TBL] [Abstract][Full Text] [Related]
25. Review of recent advances in managing periocular skin malignancies.
Trotier DC; Huang L; van Landingham SW; Burr AR; Ma VT
Front Oncol; 2024; 14():1275930. PubMed ID: 38500654
[TBL] [Abstract][Full Text] [Related]
26. Immunotherapy for keratinocyte cancers. Part II: Identification and management of cutaneous side effects of immunotherapy treatments.
Chang ALS; Zaba L; Kwong BY
J Am Acad Dermatol; 2023 Jun; 88(6):1243-1255. PubMed ID: 37268391
[TBL] [Abstract][Full Text] [Related]
27. Dermatological side effects of targeted antineoplastic therapies: a prospective study.
Agirgol S; Çaytemel C; Pilanci KN
Cutan Ocul Toxicol; 2020 Dec; 39(4):380-384. PubMed ID: 33028137
[TBL] [Abstract][Full Text] [Related]
28. Clinical management of cutaneous adverse events in patients on targeted anticancer therapies and immunotherapies: a national consensus statement by the Spanish Academy of Dermatology and Venereology and the Spanish Society of Medical Oncology.
Grávalos C; Sanmartín O; Gúrpide A; España A; Majem M; Suh Oh HJ; Aragón I; Segura S; Beato C; Botella R
Clin Transl Oncol; 2019 May; 21(5):556-571. PubMed ID: 30284232
[TBL] [Abstract][Full Text] [Related]
29. Cutaneous Adverse Reactions of Immunotherapy in Patients with Advanced Melanoma.
Nikolaou V; Tsimpidakis A; Stratigos A
Cancers (Basel); 2023 Mar; 15(7):. PubMed ID: 37046745
[TBL] [Abstract][Full Text] [Related]
30. Association between antibiotics and adverse oncological outcomes in patients receiving targeted or immune-based therapy for hepatocellular carcinoma.
Pinato DJ; Li X; Mishra-Kalyani P; D'Alessio A; Fulgenzi CAM; Scheiner B; Pinter M; Wei G; Schneider J; Rivera DR; Pazdur R; Theoret MR; Casak S; Lemery S; Fashoyin-Aje L; Cortellini A; Pelosof L
JHEP Rep; 2023 Jun; 5(6):100747. PubMed ID: 37197442
[TBL] [Abstract][Full Text] [Related]
31. Drug eruptions with novel targeted therapies - immune checkpoint and EGFR inhibitors.
Pospischil I; Hoetzenecker W
J Dtsch Dermatol Ges; 2021 Nov; 19(11):1621-1643. PubMed ID: 34811916
[TBL] [Abstract][Full Text] [Related]
32. [Advances in immunotherapy for metastatic melanoma].
Oláh J
Magy Onkol; 2017 Jun; 61(2):132-136. PubMed ID: 28585614
[TBL] [Abstract][Full Text] [Related]
33. [Personalized medicine in the treatment of periocular tumors : Targeted treatment and use of immune checkpoint inhibitors].
Rokohl AC; Koch KR; Mor JM; Loreck N; Schlaak M; Mauch C; Bechrakis NE; Mohi A; Kakkassery V; Heindl LM
Ophthalmologe; 2020 Jun; 117(6):521-527. PubMed ID: 31938823
[TBL] [Abstract][Full Text] [Related]
34. Combination checkpoint blockade for metastatic cutaneous malignancies in kidney transplant recipients.
Trager MH; Coley SM; Dube G; Khan S; Ingham M; Samie FH; Geskin LJ; McDonnell D; Brouder D; Saenger Y; Carvajal R
J Immunother Cancer; 2020 Jun; 8(1):. PubMed ID: 32503950
[TBL] [Abstract][Full Text] [Related]
35. Neurotropic Cutaneous Malignancies: Case Report on Keratinocyte Derived Malignancies of the Head and Neck With Perineural Invasion.
Ahn GS; Hinds B; Kolb F; Reisenauer AK; Soon SL; Sepahdari AR; Bollin KB; Park SJ
Front Oncol; 2022; 12():846278. PubMed ID: 35677168
[TBL] [Abstract][Full Text] [Related]
36. The Next Immune-Checkpoint Inhibitors: PD-1/PD-L1 Blockade in Melanoma.
Mahoney KM; Freeman GJ; McDermott DF
Clin Ther; 2015 Apr; 37(4):764-82. PubMed ID: 25823918
[TBL] [Abstract][Full Text] [Related]
37. Comparative efficacy analysis identifies immune checkpoint blockade as a new survival benchmark in advanced cutaneous squamous cell carcinoma.
Petzold A; Steeb T; Wessely A; Schatton T; Berking C; Heppt MV
Eur J Cancer; 2022 Jul; 170():42-53. PubMed ID: 35594611
[TBL] [Abstract][Full Text] [Related]
38. Cardiotoxicity of Systemic Melanoma Treatments.
Mukunda N; Vallabhaneni S; Lefebvre B; Fradley MG
Curr Treat Options Oncol; 2022 Feb; 23(2):240-253. PubMed ID: 35192138
[TBL] [Abstract][Full Text] [Related]
39. Cutaneous adverse reactions linked to targeted anticancer therapies bortezomib and lenalidomide for multiple myeloma: new drugs, old side effects.
Patrizi A; Venturi M; Dika E; Maibach H; Tacchetti P; Brandi G
Cutan Ocul Toxicol; 2014 Mar; 33(1):1-6. PubMed ID: 23638756
[TBL] [Abstract][Full Text] [Related]
40. Cutaneous Adverse Events of Targeted Therapies for Hematolymphoid Malignancies.
Ransohoff JD; Kwong BY
Clin Lymphoma Myeloma Leuk; 2017 Dec; 17(12):834-851. PubMed ID: 28918995
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
